Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Safer dialysis for bleeding patients? citrate vs. heparin tested

NCT ID NCT03562754

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested two ways to prevent blood clots during dialysis in 60 patients at high risk of bleeding. One method used a special blood thinner called citrate, the other used a low dose of standard heparin. The goal was to see which approach allowed dialysis to run longer and more safely. Results could help doctors choose the best option for fragile patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
citrate (regional citrate anticoagulation) versus low-dose heparin
What this could lead to
If successful, this could show that citrate is a safer blood-thinner option during dialysis for patients at risk of bleeding.
What could go wrong
This is a small, single-center trial with only 60 participants, so results may not apply broadly. Both methods have risks like clotting or metabolic issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2019

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient has been correctly informed. * The patient must have given his/her informed and signed consent. * The legal guardian or trusted-person of an adult under guardianship must have given their informed and signed consent. * The patient has health insurance coverage via the French social security system. * The patient is at least 18 years old. * The patient is at bleeding risk; the bleeding risk is defined by the clinical situation and according to predefined clinical situations (before or after surgery or biopsy, hemorrhage). * The patient requires an intermittent hemodialysis in a nephrology ICU setting. Exclusion Criteria: * The patient is participating in, or has participated in over the past three months, another interventional trial. * The patient is in an exclusion period determined by a previous study. * The patient is under judicial protection. * The parents (or legal guardian) of the patient refuse to sign the consent. * It is impossible to correctly inform the patient/parents (or legal guardian) of the patient (language barrier). * Contraindication to heparin treatment. * Indication of continuous dialysis in ICU. * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemodialysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodialysis

Contacts and locations

Locations

  • CHU Nimes

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.